|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Melanoma (Skin) | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Melanoma | |||||
| 3 | More general conditions related to this trial | ||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms, Germ Cell and Embryonal | |||||
| Neoplasms, Nerve Tissue | |||||
| Neuroectodermal Tumors | |||||
| Neuroendocrine Tumors | |||||
| Nevi and Melanomas | |||||
| 4 | Interventions listed in this trial | ||||
| bevacizumab | |||||
| imatinib mesylate | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Imatinib | |||||
| 6 | More general drug interventions related to this trial | ||||
| Angiogenesis Inhibitors | |||||
| Angiogenesis Modulating Agents | |||||
| Antineoplastic Agents | |||||
| Enzyme Inhibitors | |||||
| Growth Inhibitors | |||||
| Growth Substances | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Protein Kinase Inhibitors | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| University of Pennsylvania | |||||
| National Cancer Institute (NCI) | |||||